TOP 100 SWISS STARTUP AWARD

Resistell was selected as one of ten new startups have been selected for Venture Leaders Life Sciences 2019. Chosen from among the most-promising life sciences startups in Switzerland, the team will embark on a packed, week-long roadshow in Boston. The startups will also pitch at the Startup Champions Seed Night event in Lausanne on 11 April.

"Enough time has been wasted issuing warnings about antibiotic resistance. The moment has come to do something about it” The Economist

Bilan selected Resistell as one of the Top 50 Swiss startups in which to invest in 2019! We are proud to be on the prestigious list with our rapid AST technology!

We thank everyone who visited our scientific presentation in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). We are looking forward to all new future partnerships and collaborations!

We invite you to meet us in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). For more details please visit https://amr-conference.com

The jury of industry experts and investors selected Resistell to receive the highest level of Venture Kick’s financial support to bring their businesses to market.

Resistell has closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test.